Testing two immune-boosting drugs for bladder cancer that hasn't responded to standard treatment

Plain-English translation of NCT06503614 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether combining two medications— and —can help treat non-muscle-invasive bladder cancer in patients whose cancer has come back or didn't respond to standard BCG therapy. Both medications work by boosting your immune system to fight cancer cells. You would receive these medications as intravenous infusions (through a vein) once per month for up to one year.

Many patients with non-muscle-invasive bladder cancer do not respond well enough to the standard BCG treatment, and their cancer comes back or persists. This trial is exploring whether this medication combination can offer a better option for these patients who need a new treatment approach.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with non-muscle-invasive bladder cancer that has not responded to or has recurred after adequate BCG therapy
your doctor has determined you are not a good candidate for bladder removal surgery, or you have chosen not to have this surgery
you have had your visible tumors completely removed within 60 days before the trial starts
you are willing and able to attend monthly visits and follow all study requirements for up to one year

You likely don't qualify if…

you have received prior immune checkpoint inhibitor therapy (such as PD-1 or PD-L1 blockers)
you have muscle-invasive bladder cancer or cancer that has spread beyond the bladder
you have received more than two previous lines of chemotherapy or other treatments for bladder cancer
you have significant health problems that would prevent you from tolerating the medications or attending study visits

What participation looks like

If you join this trial, you would come to the clinic approximately once per month for up to 12 months to receive two intravenous infusions, each lasting about 1–2 hours. You would have regular check-ups, blood tests, and imaging scans to monitor how the treatment is working and how you are tolerating it. The trial will continue until your cancer progresses, you experience unacceptable side effects, or you complete the full year of treatment.

AI-generated summary from trial data · Jul 6, 2026 · Not medical advice

Trial locations(4 sites)

United States

Moffitt Cancer Center, Tampa, Florida

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Icahn School of Medicine at Mount Sinai, New York, New York

Weill Cornell Medical Center, New York, New York